Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE (ACCRUE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01098591|
Recruitment Status : Completed
First Posted : April 5, 2010
Last Update Posted : July 13, 2021
|Condition or disease||Intervention/treatment|
|Ischemic Heart Disease||Other: cell therapy|
- Background: Many clinical trials and meta-analyses presented moderate but significant improvement of the left ventricular ejection fraction (LVEF) after intracoronary autologous bone-marrow (BM) or peripheral blood origin stem cells transfer. However, it remains controversial, whether this beneficial effects is comparable with the intramyocardial delivery of the stem cells, or could be maintained during moderate and long term follow-up. The BOOST trial suggested that cardiac stem cell therapy did not improve LVEF at 5-year follow-up. By contrast, BALANCE study showed a long sustained benefit of BM-stem cells treatment. Due to these divergent outcomes of the presented trials, the aim of the present meta-analysis is to compare the safety and effectiveness of the cardiac stem cell therapy in different patient population, delivery mode and cell type, to find out, which patients with which therapy mode can have the greatest benefit from cardiac stem cell therapy.
- Study design: individual patient data meta-analysis
- Data sources: European Centre performing human cardiac stem cell therapy have been contacted calling for participation.
- Methods: Individual data gathering and entering into the database for a pooled analysis. The meta-analysis will be done in line with recommendation from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses guidelines with Review Manager 5.0. Fixed-effect model will be used.
|Study Type :||Observational|
|Actual Enrollment :||3500 participants|
|Official Title:||Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE|
|Actual Study Start Date :||November 2007|
|Actual Primary Completion Date :||December 2020|
|Actual Study Completion Date :||December 2020|
Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
Other: cell therapy
Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
Other: cell therapy
- Freedom from occurrence of major adverse cardiac and cerebrovascular events (MACCE), including all-cause death, re-infarction, revascularization and stroke [ Time Frame: 12 months ]MACCE is defined as all-cause death, re-infarction, revascularization and stroke
- Hard clinical end point [ Time Frame: 12 months ]all-cause death, re-infarction and stroke
- Changes in end-diastolic volume [ Time Frame: 12 months ]End-diastolic volume is an index of ventricular remodeling
- Changes in end-systolic volume [ Time Frame: 12 months ]Index of ventricular systolic performance
- Changes in ejection fraction [ Time Frame: 12 months ]Improvement of systolic cardiac function after cell therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01098591
|Medical University of Vienna|
|Vienna, Austria, 1090|
|Principal Investigator:||Mariann Gyongyosi, MD||Medical University of Vienna|